Global Gadolinium Contrast Media Market

Gadolinium Contrast Media Comprehensive Study by Application (CT (Computer Tomography), MRI (Magnetic Resonance Imaging), Ultrasound., X-ray), Indication (Cardiovascular Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, Nephrological Disorders), Contract Agent Types (Linear Non-Ionic Agent, Linear Ionic, Macrocyclic Non-Ionic, Macrocyclic Ionic), Route of Administration (Oral, Intravascular, Rectal) Players and Region - Global Market Outlook to 2028

Gadolinium Contrast Media Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Gadolinium Contrast Media Market Overview:
Chemical substances used in magnetic resonance imaging (MRI) scans are gadolinium contrast media (also known as MRI contrast media, agents, or 'dyes'). Gadolinium contrast medium, when inserted into the body, enhances and increases the clarity of MRI images (or pictures). Gadolinium (Gd) is a rare earth metal that is difficult to obtain and has the appearance of a silvery white crystal. At room temperature, it is one of the few metals with ferromagnetic properties. Gadolinium, like the majority of rare earth metals, contains fluorescent trivalent ions. Gadolinium absorbs neutrons and is used for shielding in neutron radiography and nuclear reactors. Increased incidences of chronic diseases, the demand for image-guided procedures and diagnostics, and a large number of contrast agent approvals are all driving the growth of the contrast media industry. The use of image-guided procedures will aid in determining whether a cancer is malignant or benign. With the rising prevalence and number of cancer cases in both emerging and developed economies around the world, protocols that can assist patients in receiving a diagnosis at an earlier stage are required.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Shift To Iodinated Contrast Media/Contrast Agents

Market Growth Drivers:
Increase in the Incidences of Chronic Diseases and Increasing Demand for Early Diagnosis and Rising of CT and MRI Examinations

Challenges:
Technological Advancements in Imaging Solutions and Restriction and Withdrawal of Linear Gadolinium-Based Contrast Agents

Restraints:
Side-Effects and Allergic Reactions Associated With Contrast Agents and Gadolinium-Based Contrast Agents Can Be Harmful To Human Beings in the Long-Term

Opportunities:
Large Number of Approvals for Contrast Agents and Increased Investment in R&D

Competitive Landscape:
The large and major companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Several companies are operating in the market to provide customers with better offers with various features & unique offerings. The market is a partially fragmented market with the presence of several market players and local players.
Some of the key players profiled in the report are Bayer AG (Germany), Bracco Diagnostic Inc. (Italy), GE Healthcare (United States), Guerbet Group (France), Spago Nanomedical AB (Sweden), Taejoon Pharm (South Korea), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India) and Lantheus Medical Imaging Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Sanochemia (Austria). Analyst at AMA Research see Asia Pacific Vendors to retain maximum share of Global Gadolinium Contrast Media market by 2028. Considering Market by Indication, the sub-segment i.e. Cardiovascular Disorders will boost the Gadolinium Contrast Media market. Considering Market by Contract Agent Types, the sub-segment i.e. Linear Non-Ionic Agent will boost the Gadolinium Contrast Media market. Considering Market by Route of Administration , the sub-segment i.e. Oral will boost the Gadolinium Contrast Media market.

Latest Market Insights:
Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, has announced a new partnership with CardioNavix, LLC aimed at improving patient access to cardiac PET imaging, an important diagnostic test for the detection of coronary artery disease (CAD)

Bayer and Siemens Healthineers presented the new Imaging System Interface (ISI) for magnetic resonance imaging (MRI) at this year’s European Congress of Radiology (ECR). ISI is a joint hardware and software development from Bayer and Siemens Healthineers and the first injector scanner interface for the MRI suite.

According to FDA- For some MRI exams, intravenous (IV) drugs, such as gadolinium-based contrast agents (GBCAs) are used to change the contrast of the MR image. Gadolinium-based contrast agents are rare earth metals that are usually given through an IV in the arm.

What Can be Explored with the Gadolinium Contrast Media Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Gadolinium Contrast Media Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Gadolinium Contrast Media
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Gadolinium Contrast Media market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Gadolinium Contrast Media market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Gadolinium, Suppliers of Gadolinium, Wholesalers, Distributors, and Retailers of Gadolinium, Chemical Industry, Pharmaceutical Industry, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • CT (Computer Tomography)
  • MRI (Magnetic Resonance Imaging)
  • Ultrasound.
  • X-ray
By Indication
  • Cardiovascular Disorders
  • Cancer
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Nephrological Disorders

By Contract Agent Types
  • Linear Non-Ionic Agent
  • Linear Ionic
  • Macrocyclic Non-Ionic
  • Macrocyclic Ionic

By Route of Administration
  • Oral
  • Intravascular
  • Rectal

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Incidences of Chronic Diseases
      • 3.2.2. Increasing Demand for Early Diagnosis and Rising of CT and MRI Examinations
    • 3.3. Market Challenges
      • 3.3.1. Technological Advancements in Imaging Solutions
      • 3.3.2. Restriction and Withdrawal of Linear Gadolinium-Based Contrast Agents
    • 3.4. Market Trends
      • 3.4.1. Shift To Iodinated Contrast Media/Contrast Agents
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gadolinium Contrast Media, by Application, Indication, Contract Agent Types, Route of Administration and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Gadolinium Contrast Media (Value)
      • 5.2.1. Global Gadolinium Contrast Media by: Application (Value)
        • 5.2.1.1. CT (Computer Tomography)
        • 5.2.1.2. MRI (Magnetic Resonance Imaging)
        • 5.2.1.3. Ultrasound.
        • 5.2.1.4. X-ray
      • 5.2.2. Global Gadolinium Contrast Media by: Indication (Value)
        • 5.2.2.1. Cardiovascular Disorders
        • 5.2.2.2. Cancer
        • 5.2.2.3. Gastrointestinal Disorders
        • 5.2.2.4. Musculoskeletal Disorders
        • 5.2.2.5. Neurological Disorders
        • 5.2.2.6. Nephrological Disorders
      • 5.2.3. Global Gadolinium Contrast Media by: Contract Agent Types (Value)
        • 5.2.3.1. Linear Non-Ionic Agent
        • 5.2.3.2. Linear Ionic
        • 5.2.3.3. Macrocyclic Non-Ionic
        • 5.2.3.4. Macrocyclic Ionic
      • 5.2.4. Global Gadolinium Contrast Media Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gadolinium Contrast Media (Volume)
      • 5.3.1. Global Gadolinium Contrast Media by: Application (Volume)
        • 5.3.1.1. CT (Computer Tomography)
        • 5.3.1.2. MRI (Magnetic Resonance Imaging)
        • 5.3.1.3. Ultrasound.
        • 5.3.1.4. X-ray
      • 5.3.2. Global Gadolinium Contrast Media by: Indication (Volume)
        • 5.3.2.1. Cardiovascular Disorders
        • 5.3.2.2. Cancer
        • 5.3.2.3. Gastrointestinal Disorders
        • 5.3.2.4. Musculoskeletal Disorders
        • 5.3.2.5. Neurological Disorders
        • 5.3.2.6. Nephrological Disorders
      • 5.3.3. Global Gadolinium Contrast Media by: Contract Agent Types (Volume)
        • 5.3.3.1. Linear Non-Ionic Agent
        • 5.3.3.2. Linear Ionic
        • 5.3.3.3. Macrocyclic Non-Ionic
        • 5.3.3.4. Macrocyclic Ionic
      • 5.3.4. Global Gadolinium Contrast Media Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Gadolinium Contrast Media (Price)
  • 6. Gadolinium Contrast Media: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bracco Diagnostic Inc. (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Guerbet Group (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Spago Nanomedical AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Taejoon Pharm (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daiichi Sankyo (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Unijules Life Sciences (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. J.B. Chemicals and Pharmaceuticals (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lantheus Medical Imaging Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gadolinium Contrast Media Sale, by Application, Indication, Contract Agent Types, Route of Administration and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Gadolinium Contrast Media (Value)
      • 7.2.1. Global Gadolinium Contrast Media by: Application (Value)
        • 7.2.1.1. CT (Computer Tomography)
        • 7.2.1.2. MRI (Magnetic Resonance Imaging)
        • 7.2.1.3. Ultrasound.
        • 7.2.1.4. X-ray
      • 7.2.2. Global Gadolinium Contrast Media by: Indication (Value)
        • 7.2.2.1. Cardiovascular Disorders
        • 7.2.2.2. Cancer
        • 7.2.2.3. Gastrointestinal Disorders
        • 7.2.2.4. Musculoskeletal Disorders
        • 7.2.2.5. Neurological Disorders
        • 7.2.2.6. Nephrological Disorders
      • 7.2.3. Global Gadolinium Contrast Media by: Contract Agent Types (Value)
        • 7.2.3.1. Linear Non-Ionic Agent
        • 7.2.3.2. Linear Ionic
        • 7.2.3.3. Macrocyclic Non-Ionic
        • 7.2.3.4. Macrocyclic Ionic
      • 7.2.4. Global Gadolinium Contrast Media Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gadolinium Contrast Media (Volume)
      • 7.3.1. Global Gadolinium Contrast Media by: Application (Volume)
        • 7.3.1.1. CT (Computer Tomography)
        • 7.3.1.2. MRI (Magnetic Resonance Imaging)
        • 7.3.1.3. Ultrasound.
        • 7.3.1.4. X-ray
      • 7.3.2. Global Gadolinium Contrast Media by: Indication (Volume)
        • 7.3.2.1. Cardiovascular Disorders
        • 7.3.2.2. Cancer
        • 7.3.2.3. Gastrointestinal Disorders
        • 7.3.2.4. Musculoskeletal Disorders
        • 7.3.2.5. Neurological Disorders
        • 7.3.2.6. Nephrological Disorders
      • 7.3.3. Global Gadolinium Contrast Media by: Contract Agent Types (Volume)
        • 7.3.3.1. Linear Non-Ionic Agent
        • 7.3.3.2. Linear Ionic
        • 7.3.3.3. Macrocyclic Non-Ionic
        • 7.3.3.4. Macrocyclic Ionic
      • 7.3.4. Global Gadolinium Contrast Media Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Gadolinium Contrast Media (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gadolinium Contrast Media: by Application(USD Million)
  • Table 2. Gadolinium Contrast Media CT (Computer Tomography) , by Region USD Million (2017-2022)
  • Table 3. Gadolinium Contrast Media MRI (Magnetic Resonance Imaging) , by Region USD Million (2017-2022)
  • Table 4. Gadolinium Contrast Media Ultrasound. , by Region USD Million (2017-2022)
  • Table 5. Gadolinium Contrast Media X-ray , by Region USD Million (2017-2022)
  • Table 6. Gadolinium Contrast Media: by Indication(USD Million)
  • Table 7. Gadolinium Contrast Media Cardiovascular Disorders , by Region USD Million (2017-2022)
  • Table 8. Gadolinium Contrast Media Cancer , by Region USD Million (2017-2022)
  • Table 9. Gadolinium Contrast Media Gastrointestinal Disorders , by Region USD Million (2017-2022)
  • Table 10. Gadolinium Contrast Media Musculoskeletal Disorders , by Region USD Million (2017-2022)
  • Table 11. Gadolinium Contrast Media Neurological Disorders , by Region USD Million (2017-2022)
  • Table 12. Gadolinium Contrast Media Nephrological Disorders , by Region USD Million (2017-2022)
  • Table 13. Gadolinium Contrast Media: by Contract Agent Types(USD Million)
  • Table 14. Gadolinium Contrast Media Linear Non-Ionic Agent , by Region USD Million (2017-2022)
  • Table 15. Gadolinium Contrast Media Linear Ionic , by Region USD Million (2017-2022)
  • Table 16. Gadolinium Contrast Media Macrocyclic Non-Ionic , by Region USD Million (2017-2022)
  • Table 17. Gadolinium Contrast Media Macrocyclic Ionic , by Region USD Million (2017-2022)
  • Table 18. South America Gadolinium Contrast Media, by Country USD Million (2017-2022)
  • Table 19. South America Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 20. South America Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 21. South America Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 22. South America Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 23. Brazil Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 24. Brazil Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 25. Brazil Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 26. Brazil Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 27. Argentina Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 28. Argentina Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 29. Argentina Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 30. Argentina Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 31. Rest of South America Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 32. Rest of South America Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 33. Rest of South America Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 34. Rest of South America Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 35. Asia Pacific Gadolinium Contrast Media, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 37. Asia Pacific Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 38. Asia Pacific Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 39. Asia Pacific Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 40. China Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 41. China Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 42. China Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 43. China Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 44. Japan Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 45. Japan Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 46. Japan Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 47. Japan Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 48. India Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 49. India Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 50. India Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 51. India Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 52. South Korea Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 53. South Korea Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 54. South Korea Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 55. South Korea Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 56. Taiwan Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 57. Taiwan Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 58. Taiwan Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 59. Taiwan Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 60. Australia Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 61. Australia Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 62. Australia Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 63. Australia Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 68. Europe Gadolinium Contrast Media, by Country USD Million (2017-2022)
  • Table 69. Europe Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 70. Europe Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 71. Europe Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 72. Europe Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 73. Germany Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 74. Germany Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 75. Germany Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 76. Germany Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 77. France Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 78. France Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 79. France Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 80. France Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 81. Italy Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 82. Italy Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 83. Italy Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 84. Italy Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 85. United Kingdom Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 86. United Kingdom Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 87. United Kingdom Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 88. United Kingdom Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 89. Netherlands Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 90. Netherlands Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 91. Netherlands Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 92. Netherlands Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 93. Rest of Europe Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 94. Rest of Europe Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 95. Rest of Europe Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 96. Rest of Europe Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 97. MEA Gadolinium Contrast Media, by Country USD Million (2017-2022)
  • Table 98. MEA Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 99. MEA Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 100. MEA Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 101. MEA Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 102. Middle East Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 103. Middle East Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 104. Middle East Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 105. Middle East Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 106. Africa Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 107. Africa Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 108. Africa Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 109. Africa Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 110. North America Gadolinium Contrast Media, by Country USD Million (2017-2022)
  • Table 111. North America Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 112. North America Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 113. North America Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 114. North America Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 115. United States Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 116. United States Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 117. United States Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 118. United States Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 119. Canada Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 120. Canada Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 121. Canada Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 122. Canada Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 123. Mexico Gadolinium Contrast Media, by Application USD Million (2017-2022)
  • Table 124. Mexico Gadolinium Contrast Media, by Indication USD Million (2017-2022)
  • Table 125. Mexico Gadolinium Contrast Media, by Contract Agent Types USD Million (2017-2022)
  • Table 126. Mexico Gadolinium Contrast Media, by Route of Administration USD Million (2017-2022)
  • Table 127. Gadolinium Contrast Media Sales: by Application(K Tons)
  • Table 128. Gadolinium Contrast Media Sales CT (Computer Tomography) , by Region K Tons (2017-2022)
  • Table 129. Gadolinium Contrast Media Sales MRI (Magnetic Resonance Imaging) , by Region K Tons (2017-2022)
  • Table 130. Gadolinium Contrast Media Sales Ultrasound. , by Region K Tons (2017-2022)
  • Table 131. Gadolinium Contrast Media Sales X-ray , by Region K Tons (2017-2022)
  • Table 132. Gadolinium Contrast Media Sales: by Indication(K Tons)
  • Table 133. Gadolinium Contrast Media Sales Cardiovascular Disorders , by Region K Tons (2017-2022)
  • Table 134. Gadolinium Contrast Media Sales Cancer , by Region K Tons (2017-2022)
  • Table 135. Gadolinium Contrast Media Sales Gastrointestinal Disorders , by Region K Tons (2017-2022)
  • Table 136. Gadolinium Contrast Media Sales Musculoskeletal Disorders , by Region K Tons (2017-2022)
  • Table 137. Gadolinium Contrast Media Sales Neurological Disorders , by Region K Tons (2017-2022)
  • Table 138. Gadolinium Contrast Media Sales Nephrological Disorders , by Region K Tons (2017-2022)
  • Table 139. Gadolinium Contrast Media Sales: by Contract Agent Types(K Tons)
  • Table 140. Gadolinium Contrast Media Sales Linear Non-Ionic Agent , by Region K Tons (2017-2022)
  • Table 141. Gadolinium Contrast Media Sales Linear Ionic , by Region K Tons (2017-2022)
  • Table 142. Gadolinium Contrast Media Sales Macrocyclic Non-Ionic , by Region K Tons (2017-2022)
  • Table 143. Gadolinium Contrast Media Sales Macrocyclic Ionic , by Region K Tons (2017-2022)
  • Table 144. South America Gadolinium Contrast Media Sales, by Country K Tons (2017-2022)
  • Table 145. South America Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 146. South America Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 147. South America Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 148. South America Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 149. Brazil Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 150. Brazil Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 151. Brazil Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 152. Brazil Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 153. Argentina Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 154. Argentina Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 155. Argentina Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 156. Argentina Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 157. Rest of South America Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 158. Rest of South America Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 159. Rest of South America Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 160. Rest of South America Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 161. Asia Pacific Gadolinium Contrast Media Sales, by Country K Tons (2017-2022)
  • Table 162. Asia Pacific Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 163. Asia Pacific Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 164. Asia Pacific Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 165. Asia Pacific Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 166. China Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 167. China Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 168. China Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 169. China Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 170. Japan Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 171. Japan Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 172. Japan Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 173. Japan Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 174. India Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 175. India Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 176. India Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 177. India Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 178. South Korea Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 179. South Korea Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 180. South Korea Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 181. South Korea Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 182. Taiwan Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 183. Taiwan Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 184. Taiwan Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 185. Taiwan Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 186. Australia Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 187. Australia Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 188. Australia Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 189. Australia Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 190. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 191. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 192. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 193. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 194. Europe Gadolinium Contrast Media Sales, by Country K Tons (2017-2022)
  • Table 195. Europe Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 196. Europe Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 197. Europe Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 198. Europe Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 199. Germany Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 200. Germany Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 201. Germany Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 202. Germany Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 203. France Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 204. France Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 205. France Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 206. France Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 207. Italy Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 208. Italy Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 209. Italy Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 210. Italy Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 211. United Kingdom Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 212. United Kingdom Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 213. United Kingdom Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 214. United Kingdom Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 215. Netherlands Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 216. Netherlands Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 217. Netherlands Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 218. Netherlands Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 219. Rest of Europe Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 220. Rest of Europe Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 221. Rest of Europe Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 222. Rest of Europe Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 223. MEA Gadolinium Contrast Media Sales, by Country K Tons (2017-2022)
  • Table 224. MEA Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 225. MEA Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 226. MEA Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 227. MEA Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 228. Middle East Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 229. Middle East Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 230. Middle East Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 231. Middle East Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 232. Africa Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 233. Africa Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 234. Africa Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 235. Africa Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 236. North America Gadolinium Contrast Media Sales, by Country K Tons (2017-2022)
  • Table 237. North America Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 238. North America Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 239. North America Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 240. North America Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 241. United States Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 242. United States Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 243. United States Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 244. United States Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 245. Canada Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 246. Canada Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 247. Canada Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 248. Canada Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 249. Mexico Gadolinium Contrast Media Sales, by Application K Tons (2017-2022)
  • Table 250. Mexico Gadolinium Contrast Media Sales, by Indication K Tons (2017-2022)
  • Table 251. Mexico Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2017-2022)
  • Table 252. Mexico Gadolinium Contrast Media Sales, by Route of Administration K Tons (2017-2022)
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Gadolinium Contrast Media: by Application(USD Million)
  • Table 264. Gadolinium Contrast Media CT (Computer Tomography) , by Region USD Million (2023-2028)
  • Table 265. Gadolinium Contrast Media MRI (Magnetic Resonance Imaging) , by Region USD Million (2023-2028)
  • Table 266. Gadolinium Contrast Media Ultrasound. , by Region USD Million (2023-2028)
  • Table 267. Gadolinium Contrast Media X-ray , by Region USD Million (2023-2028)
  • Table 268. Gadolinium Contrast Media: by Indication(USD Million)
  • Table 269. Gadolinium Contrast Media Cardiovascular Disorders , by Region USD Million (2023-2028)
  • Table 270. Gadolinium Contrast Media Cancer , by Region USD Million (2023-2028)
  • Table 271. Gadolinium Contrast Media Gastrointestinal Disorders , by Region USD Million (2023-2028)
  • Table 272. Gadolinium Contrast Media Musculoskeletal Disorders , by Region USD Million (2023-2028)
  • Table 273. Gadolinium Contrast Media Neurological Disorders , by Region USD Million (2023-2028)
  • Table 274. Gadolinium Contrast Media Nephrological Disorders , by Region USD Million (2023-2028)
  • Table 275. Gadolinium Contrast Media: by Contract Agent Types(USD Million)
  • Table 276. Gadolinium Contrast Media Linear Non-Ionic Agent , by Region USD Million (2023-2028)
  • Table 277. Gadolinium Contrast Media Linear Ionic , by Region USD Million (2023-2028)
  • Table 278. Gadolinium Contrast Media Macrocyclic Non-Ionic , by Region USD Million (2023-2028)
  • Table 279. Gadolinium Contrast Media Macrocyclic Ionic , by Region USD Million (2023-2028)
  • Table 280. South America Gadolinium Contrast Media, by Country USD Million (2023-2028)
  • Table 281. South America Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 282. South America Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 283. South America Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 284. South America Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 285. Brazil Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 286. Brazil Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 287. Brazil Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 288. Brazil Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 289. Argentina Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 290. Argentina Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 291. Argentina Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 292. Argentina Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 293. Rest of South America Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 294. Rest of South America Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 295. Rest of South America Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 296. Rest of South America Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 297. Asia Pacific Gadolinium Contrast Media, by Country USD Million (2023-2028)
  • Table 298. Asia Pacific Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 299. Asia Pacific Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 300. Asia Pacific Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 301. Asia Pacific Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 302. China Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 303. China Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 304. China Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 305. China Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 306. Japan Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 307. Japan Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 308. Japan Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 309. Japan Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 310. India Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 311. India Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 312. India Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 313. India Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 314. South Korea Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 315. South Korea Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 316. South Korea Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 317. South Korea Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 318. Taiwan Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 319. Taiwan Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 320. Taiwan Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 321. Taiwan Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 322. Australia Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 323. Australia Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 324. Australia Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 325. Australia Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 326. Rest of Asia-Pacific Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 327. Rest of Asia-Pacific Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 328. Rest of Asia-Pacific Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 329. Rest of Asia-Pacific Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 330. Europe Gadolinium Contrast Media, by Country USD Million (2023-2028)
  • Table 331. Europe Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 332. Europe Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 333. Europe Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 334. Europe Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 335. Germany Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 336. Germany Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 337. Germany Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 338. Germany Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 339. France Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 340. France Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 341. France Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 342. France Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 343. Italy Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 344. Italy Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 345. Italy Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 346. Italy Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 347. United Kingdom Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 348. United Kingdom Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 349. United Kingdom Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 350. United Kingdom Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 351. Netherlands Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 352. Netherlands Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 353. Netherlands Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 354. Netherlands Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 355. Rest of Europe Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 356. Rest of Europe Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 357. Rest of Europe Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 358. Rest of Europe Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 359. MEA Gadolinium Contrast Media, by Country USD Million (2023-2028)
  • Table 360. MEA Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 361. MEA Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 362. MEA Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 363. MEA Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 364. Middle East Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 365. Middle East Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 366. Middle East Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 367. Middle East Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 368. Africa Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 369. Africa Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 370. Africa Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 371. Africa Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 372. North America Gadolinium Contrast Media, by Country USD Million (2023-2028)
  • Table 373. North America Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 374. North America Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 375. North America Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 376. North America Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 377. United States Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 378. United States Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 379. United States Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 380. United States Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 381. Canada Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 382. Canada Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 383. Canada Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 384. Canada Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 385. Mexico Gadolinium Contrast Media, by Application USD Million (2023-2028)
  • Table 386. Mexico Gadolinium Contrast Media, by Indication USD Million (2023-2028)
  • Table 387. Mexico Gadolinium Contrast Media, by Contract Agent Types USD Million (2023-2028)
  • Table 388. Mexico Gadolinium Contrast Media, by Route of Administration USD Million (2023-2028)
  • Table 389. Gadolinium Contrast Media Sales: by Application(K Tons)
  • Table 390. Gadolinium Contrast Media Sales CT (Computer Tomography) , by Region K Tons (2023-2028)
  • Table 391. Gadolinium Contrast Media Sales MRI (Magnetic Resonance Imaging) , by Region K Tons (2023-2028)
  • Table 392. Gadolinium Contrast Media Sales Ultrasound. , by Region K Tons (2023-2028)
  • Table 393. Gadolinium Contrast Media Sales X-ray , by Region K Tons (2023-2028)
  • Table 394. Gadolinium Contrast Media Sales: by Indication(K Tons)
  • Table 395. Gadolinium Contrast Media Sales Cardiovascular Disorders , by Region K Tons (2023-2028)
  • Table 396. Gadolinium Contrast Media Sales Cancer , by Region K Tons (2023-2028)
  • Table 397. Gadolinium Contrast Media Sales Gastrointestinal Disorders , by Region K Tons (2023-2028)
  • Table 398. Gadolinium Contrast Media Sales Musculoskeletal Disorders , by Region K Tons (2023-2028)
  • Table 399. Gadolinium Contrast Media Sales Neurological Disorders , by Region K Tons (2023-2028)
  • Table 400. Gadolinium Contrast Media Sales Nephrological Disorders , by Region K Tons (2023-2028)
  • Table 401. Gadolinium Contrast Media Sales: by Contract Agent Types(K Tons)
  • Table 402. Gadolinium Contrast Media Sales Linear Non-Ionic Agent , by Region K Tons (2023-2028)
  • Table 403. Gadolinium Contrast Media Sales Linear Ionic , by Region K Tons (2023-2028)
  • Table 404. Gadolinium Contrast Media Sales Macrocyclic Non-Ionic , by Region K Tons (2023-2028)
  • Table 405. Gadolinium Contrast Media Sales Macrocyclic Ionic , by Region K Tons (2023-2028)
  • Table 406. South America Gadolinium Contrast Media Sales, by Country K Tons (2023-2028)
  • Table 407. South America Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 408. South America Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 409. South America Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 410. South America Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 411. Brazil Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 412. Brazil Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 413. Brazil Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 414. Brazil Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 415. Argentina Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 416. Argentina Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 417. Argentina Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 418. Argentina Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 419. Rest of South America Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 420. Rest of South America Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 421. Rest of South America Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 422. Rest of South America Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 423. Asia Pacific Gadolinium Contrast Media Sales, by Country K Tons (2023-2028)
  • Table 424. Asia Pacific Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 425. Asia Pacific Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 426. Asia Pacific Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 427. Asia Pacific Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 428. China Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 429. China Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 430. China Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 431. China Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 432. Japan Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 433. Japan Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 434. Japan Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 435. Japan Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 436. India Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 437. India Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 438. India Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 439. India Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 440. South Korea Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 441. South Korea Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 442. South Korea Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 443. South Korea Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 444. Taiwan Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 445. Taiwan Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 446. Taiwan Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 447. Taiwan Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 448. Australia Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 449. Australia Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 450. Australia Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 451. Australia Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 452. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 453. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 454. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 455. Rest of Asia-Pacific Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 456. Europe Gadolinium Contrast Media Sales, by Country K Tons (2023-2028)
  • Table 457. Europe Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 458. Europe Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 459. Europe Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 460. Europe Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 461. Germany Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 462. Germany Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 463. Germany Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 464. Germany Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 465. France Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 466. France Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 467. France Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 468. France Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 469. Italy Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 470. Italy Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 471. Italy Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 472. Italy Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 473. United Kingdom Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 474. United Kingdom Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 475. United Kingdom Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 476. United Kingdom Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 477. Netherlands Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 478. Netherlands Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 479. Netherlands Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 480. Netherlands Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 481. Rest of Europe Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 482. Rest of Europe Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 483. Rest of Europe Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 484. Rest of Europe Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 485. MEA Gadolinium Contrast Media Sales, by Country K Tons (2023-2028)
  • Table 486. MEA Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 487. MEA Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 488. MEA Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 489. MEA Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 490. Middle East Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 491. Middle East Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 492. Middle East Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 493. Middle East Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 494. Africa Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 495. Africa Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 496. Africa Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 497. Africa Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 498. North America Gadolinium Contrast Media Sales, by Country K Tons (2023-2028)
  • Table 499. North America Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 500. North America Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 501. North America Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 502. North America Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 503. United States Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 504. United States Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 505. United States Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 506. United States Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 507. Canada Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 508. Canada Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 509. Canada Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 510. Canada Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 511. Mexico Gadolinium Contrast Media Sales, by Application K Tons (2023-2028)
  • Table 512. Mexico Gadolinium Contrast Media Sales, by Indication K Tons (2023-2028)
  • Table 513. Mexico Gadolinium Contrast Media Sales, by Contract Agent Types K Tons (2023-2028)
  • Table 514. Mexico Gadolinium Contrast Media Sales, by Route of Administration K Tons (2023-2028)
  • Table 515. Research Programs/Design for This Report
  • Table 516. Key Data Information from Secondary Sources
  • Table 517. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gadolinium Contrast Media: by Application USD Million (2017-2022)
  • Figure 5. Global Gadolinium Contrast Media: by Indication USD Million (2017-2022)
  • Figure 6. Global Gadolinium Contrast Media: by Contract Agent Types USD Million (2017-2022)
  • Figure 7. South America Gadolinium Contrast Media Share (%), by Country
  • Figure 8. Asia Pacific Gadolinium Contrast Media Share (%), by Country
  • Figure 9. Europe Gadolinium Contrast Media Share (%), by Country
  • Figure 10. MEA Gadolinium Contrast Media Share (%), by Country
  • Figure 11. North America Gadolinium Contrast Media Share (%), by Country
  • Figure 12. Global Gadolinium Contrast Media: by Application K Tons (2017-2022)
  • Figure 13. Global Gadolinium Contrast Media: by Indication K Tons (2017-2022)
  • Figure 14. Global Gadolinium Contrast Media: by Contract Agent Types K Tons (2017-2022)
  • Figure 15. South America Gadolinium Contrast Media Share (%), by Country
  • Figure 16. Asia Pacific Gadolinium Contrast Media Share (%), by Country
  • Figure 17. Europe Gadolinium Contrast Media Share (%), by Country
  • Figure 18. MEA Gadolinium Contrast Media Share (%), by Country
  • Figure 19. North America Gadolinium Contrast Media Share (%), by Country
  • Figure 20. Global Gadolinium Contrast Media share by Players 2022 (%)
  • Figure 21. Global Gadolinium Contrast Media share by Players (Top 3) 2022(%)
  • Figure 22. Global Gadolinium Contrast Media share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 26. Bracco Diagnostic Inc. (Italy) Revenue, Net Income and Gross profit
  • Figure 27. Bracco Diagnostic Inc. (Italy) Revenue: by Geography 2022
  • Figure 28. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 29. GE Healthcare (United States) Revenue: by Geography 2022
  • Figure 30. Guerbet Group (France) Revenue, Net Income and Gross profit
  • Figure 31. Guerbet Group (France) Revenue: by Geography 2022
  • Figure 32. Spago Nanomedical AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 33. Spago Nanomedical AB (Sweden) Revenue: by Geography 2022
  • Figure 34. Taejoon Pharm (South Korea) Revenue, Net Income and Gross profit
  • Figure 35. Taejoon Pharm (South Korea) Revenue: by Geography 2022
  • Figure 36. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Daiichi Sankyo (Japan) Revenue: by Geography 2022
  • Figure 38. Unijules Life Sciences (India) Revenue, Net Income and Gross profit
  • Figure 39. Unijules Life Sciences (India) Revenue: by Geography 2022
  • Figure 40. J.B. Chemicals and Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 41. J.B. Chemicals and Pharmaceuticals (India) Revenue: by Geography 2022
  • Figure 42. Lantheus Medical Imaging Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Lantheus Medical Imaging Inc. (United States) Revenue: by Geography 2022
  • Figure 44. Global Gadolinium Contrast Media: by Application USD Million (2023-2028)
  • Figure 45. Global Gadolinium Contrast Media: by Indication USD Million (2023-2028)
  • Figure 46. Global Gadolinium Contrast Media: by Contract Agent Types USD Million (2023-2028)
  • Figure 47. South America Gadolinium Contrast Media Share (%), by Country
  • Figure 48. Asia Pacific Gadolinium Contrast Media Share (%), by Country
  • Figure 49. Europe Gadolinium Contrast Media Share (%), by Country
  • Figure 50. MEA Gadolinium Contrast Media Share (%), by Country
  • Figure 51. North America Gadolinium Contrast Media Share (%), by Country
  • Figure 52. Global Gadolinium Contrast Media: by Application K Tons (2023-2028)
  • Figure 53. Global Gadolinium Contrast Media: by Indication K Tons (2023-2028)
  • Figure 54. Global Gadolinium Contrast Media: by Contract Agent Types K Tons (2023-2028)
  • Figure 55. South America Gadolinium Contrast Media Share (%), by Country
  • Figure 56. Asia Pacific Gadolinium Contrast Media Share (%), by Country
  • Figure 57. Europe Gadolinium Contrast Media Share (%), by Country
  • Figure 58. MEA Gadolinium Contrast Media Share (%), by Country
  • Figure 59. North America Gadolinium Contrast Media Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Bracco Diagnostic Inc. (Italy)
  • GE Healthcare (United States)
  • Guerbet Group (France)
  • Spago Nanomedical AB (Sweden)
  • Taejoon Pharm (South Korea)
  • Daiichi Sankyo (Japan)
  • Unijules Life Sciences (India)
  • J.B. Chemicals and Pharmaceuticals (India)
  • Lantheus Medical Imaging Inc. (United States)
Additional players considered in the study are as follows:
Sanochemia (Austria)
Select User Access Type

Key Highlights of Report


May 2023 187 Pages 54 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gadolinium Contrast Media Market Quantitative research analysis
Global Gadolinium Contrast Media Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Gadolinium Contrast Media market are Bayer AG (Germany), Bracco Diagnostic Inc. (Italy), GE Healthcare (United States), Guerbet Group (France), Spago Nanomedical AB (Sweden), Taejoon Pharm (South Korea), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India) and Lantheus Medical Imaging Inc. (United States), to name a few.
"Shift To Iodinated Contrast Media/Contrast Agents" is seen as one of major influencing trends for Gadolinium Contrast Media Market during projected period 2022-2028.

Know More About Global Gadolinium Contrast Media Market Report?

Have a Query? Click Here

Other Related Reports

Deet Free Insect Repellent Comprehensive Study by Type (Sprays/Aerosols, Vaporizers, Creams, Other), Distribution Channel (Convenience Stores, E-commerce, Hypermarket/Supermarket, Specialty Stores), ...
$ 3650
Potassium Stearate Comprehensive Study by Function (Cleansing, Emulsifying, Surfactant), End Use (Food and Beverages, Personal Care, Cosmetics, Others), Sales Channel (Direct, Indirect) Players and R...
$ 3500
Thermosetting Plastics Comprehensive Study by Type (Alkyds, Epoxies, Amino, Polyurethane, Phenolic, Vinyl Ester Resin, Others), Application (Construction, Adhesives and Sealants, Electronics & Applia...
$ 3650
Dipropylene Glycol Methyl Ether Acetate Comprehensive Study by Application (Residential, Commercial, Industrial), Products (Inks, Paints and Coatings, Cleaners, Others), End Use (Solvent, Coalescing ...
$ 3350
Mercaptobenzothiazole Comprehensive Study by Type (Sodium 2 – Mercaptobenzothiazole, Zinc 2 – Mercaptobenzothiazole), Application (Residential, Industrial), Form (Crystal, Liquid, Powder), Industry V...
$ 3450
Erythrulose Comprehensive Study by Application (Pharmaceutical, Cosmetics and Personal Care, Others), Form (Solid, Liquid) Players and Region - Global Market Outlook to 2030
$ 3500